INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2013

Bioavailable curcumin was safely administered alongside chemotherapy in biliary and pancreatic cancer.

Sixteen pancreatic or biliary tract cancer patients who had failed standard chemotherapy received daily oral Theracurmin at either 200 mg (n = 10) or 400 mg (n = 6) with gemcitabine-based chemotherapy. Median peak plasma curcumin concentrations reached 324 ng/mL at the lower dose and 440 ng/mL at the higher dose. No unexpected adverse events occurred, and three individuals safely continued Theracurmin for more than 9 months.

Study type
Phase I clinical trial
Who was studied
16 pancreatic or biliary tract cancer patients who failed standard chemotherapy
What was measured
Safety, pharmacokinetics, and tolerability

THE PAPER

A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients.

Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kodama Y, Matsumoto S, Murakami Y, Imaizumi A, Chiba T, Nishihira J, Shibata H. Cancer Chemother Pharmacol, 2013.

PubMed 23543271 ↗DOI 10.1007/s00280-013-2151-8 ↗

Cancer

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.